In addition to being a biomarker of advanced PCa, an approach with reducing Twist1 to the physiological level is sufficient for anticancer effects,45 so inhibition of Twist1 may be a potential novel therapeutic strategy for PCa treatment. Here, TWIST1 is linked to posterior cortical atrophy.